盐酸恩沙替尼胶囊

Search documents
多只港股股价创历史新高
证券时报· 2025-08-20 05:17
Core Viewpoint - The Hong Kong stock market is currently experiencing a period of intensive mid-term earnings disclosures, leading to significant stock price fluctuations for various companies [1][2]. Group 1: Earnings Performance - As of August 20, over 800 companies have reported their mid-term earnings for 2025, with some companies seeing their stock prices soar due to better-than-expected performance, while others faced significant declines due to differing market growth expectations, indicating a "structural differentiation" in the market [2]. - Fuyao Glass and Pop Mart achieved record highs in their stock prices following strong earnings reports, with Fuyao Glass reaching HKD 69.05 per share and Pop Mart surpassing HKD 305 per share [5][9]. - Fuyao Glass reported a revenue of CNY 21.447 billion for the first half of 2025, a year-on-year increase of 16.94%, and a net profit of CNY 4.8 billion, up 37.33% [7]. - Pop Mart's revenue for the first half of 2025 was CNY 13.88 billion, a remarkable year-on-year growth of 204.4%, with an adjusted net profit of CNY 4.71 billion, up 362.8% [9]. - Chow Sang Sang's stock price surged over 27% to HKD 11.42 per share after announcing an expected net profit of HKD 900 million to HKD 920 million for the first half of 2025, compared to HKD 502 million in the same period last year [11]. Group 2: Underperforming Companies - Yancoal Australia saw its stock price drop over 9% on August 20 due to disappointing earnings results, with a reported revenue of AUD 2.675 billion, a year-on-year decrease of 15%, and a net profit of AUD 163 million, down 61% [14][16]. - The decline in Yancoal Australia's performance was attributed to a general drop in global coal prices, with the average selling price of self-produced coal falling 15% to AUD 149 per ton [16]. - Several pharmaceutical stocks also experienced declines, with companies like Simcere Pharmaceutical and Hansoh Pharmaceutical seeing drops exceeding 7% following underwhelming earnings reports [17].
多只港股股价创历史新高
Zheng Quan Shi Bao· 2025-08-20 05:09
福耀玻璃、泡泡玛特等刷新上市以来纪录 Wind数据显示,截至目前,已有超800家公司公布了2025年中期业绩,其中部分公司因业绩超预期股价 飙升,甚至刷新上市以来新高,而部分行业龙头则因市场对未来增长预期的分歧出现大幅回调,市场呈 现"结构性分化"特征。 目前,港股市场进入中期业绩密集披露期,多只港股在业绩公布后,股价波动明显。 在业绩驱动下,多只个股凭借强劲的财务数据和战略布局实现股价大涨,甚至刷新上市以来纪录。 8月20日,在港股整体表现疲软背景下,业绩表现良好的福耀玻璃、泡泡玛特等盘中大涨,股价刷新历 史纪录。 8月20日,福耀玻璃港股的股价一度攀升至69.05港元/股,刷新上市以来新高。 8月19日晚,福耀玻璃披露2025年半年报。公司上半年实现营业收入214.47亿元,同比增长16.94%;实 现归属于上市公司股东的净利润48亿元,同比增长37.33%。公司拟进行中期利润分配,拟每股分配现 金股利0.90元(含税),合计派发现金股利23.5亿元。 泡泡玛特在中期业绩公布后,公司股价一度突破300港元关口,攀升至305港元/股,刷新上市以来新 高,总市值超过4000亿港元。 兖煤澳大利亚的半年报显示, ...
“创新药第一股”半年报净利润首次下滑,同比降超三成
Xin Lang Cai Jing· 2025-08-20 01:49
8月19日晚间,贝达药业(300558.SZ)披露半年报,上半年实现营业收入17.31亿元,同比增长 15.37%;归属净利润1.4亿元,同比下降37.53%。 这是公司自2022年之后,首次在半年报出现净利润同比下滑现象。贝达药业表示,因计入当期损益的折 旧摊销等费用升高,归属净利润出现了一定程度的下降。 元。 公司在2025年半年度报告中提到,报告期内的经营业务主要围绕创新药物的研发和销售。公司已有八款 药品上市新产品,包括盐酸埃克替尼片、盐酸恩沙替尼胶囊等核心产品。 另外,甲磺酸贝福替尼胶囊和伏罗尼布片在纳入医保后销售加快,酒石酸泰瑞西利胶囊于2025年6月获 批上市。此外,公司宣布暂停开发BPB-101项目,并透露MCLA-129在肺癌领域的II期研究已完成首例 患者入组。 多款新药集中上市利好的同时,公司资金却有所承压。截至上半年末,贝达药业流动资产为13.59亿 元,低于17.57亿元的流动负债。 其中,2025年一季报营业收入为9.18亿元,同比上升24.7%;归母净利润为1.0亿元,同比上升2.0%;扣 非归母净利润为1.64亿元,同比上升83.6%。 据智通财经报道,贝达药业目前有拖欠合作方 ...
7月2日晚间重要公告一览
Xi Niu Cai Jing· 2025-07-02 10:18
Group 1 - CITIC Construction Investment has received approval from the China Securities Regulatory Commission to issue perpetual subordinated bonds with a total face value of no more than 20 billion yuan [1] - Bluefocus Technology has received a loan commitment of up to 900 million yuan from CITIC Bank for stock repurchase [1] - Huaren Pharmaceutical's subsidiary has received approval for the listing of Bumetanide raw materials, which are used to treat severe heart failure and hypertension emergencies [3] Group 2 - Betta Pharmaceuticals has received approval for the listing of Enasidenib capsules in Macau, aimed at treating ALK-positive locally advanced or metastatic non-small cell lung cancer [4] - Juewei Food plans to use 110 million yuan of idle fundraising for cash management, with an expected annual yield of 1.00%-1.89% [6] - China Huadian has successfully completed the issuance of 1 billion yuan medium-term notes with a coupon rate of 1.95% [9] Group 3 - Fosun Pharma's subsidiary has received a GMP certificate from the Belgian Federal Agency for Medicines and Health Products for the production facilities of two monoclonal antibodies [11] - China Nuclear Engineering has signed a civil engineering contract for the Taishan Nuclear Power Units 3 and 4 [13] - Kanglongda has faced administrative regulatory measures from the Zhejiang Securities Regulatory Bureau due to the failure of performance commitment parties to fulfill compensation obligations [15] Group 4 - Gaoling Information has received three invention patent certificates in the second quarter, covering various technological fields [16] - Weimais plans to use 190 million yuan of excess fundraising to increase capital in its subsidiary for building a new energy vehicle powertrain production base [17] - Huazhong Technology has received a project designation notice from a leading eVTOL manufacturer for the development and supply of an intelligent cockpit multimedia display system [19] Group 5 - Madi Technology expects a net profit of 25 million to 27 million yuan for the first half of 2025, marking a turnaround from a loss in the previous year [19] - Dazhong Mining's subsidiary has obtained a mining license for the Zhouyoufang Iron Mine, increasing production capacity to 6.5 million tons per year [20] - Zhongguancun's subsidiary has had its application for the listing of Arolol hydrochloride tablets accepted by the National Medical Products Administration [21] Group 6 - Tianhong Co. has signed a property management contract worth 15 million yuan with a local company [22] - Dong'an Power has secured nine new market designation agreements in the second quarter, with a projected total sales volume of 1.5 million units [24] - Zhujiang Co. has appointed Zhao Kun as the new deputy general manager [25] Group 7 - Jinyi Industrial has won a bid for a project worth 335 million yuan from the China Railway Shanghai Bureau Group [26] - Kangchen Pharmaceutical has received a clinical trial notification for its innovative drug KC1086, aimed at treating advanced solid tumors [27] - Changhua Group has received a project designation notice from a new energy vehicle company, with an expected total sales amount of 970 million yuan [29] Group 8 - Lingxiao Pump Industry plans to use 60 million yuan of idle funds to purchase financial products [31] - Mould Technology has received a project designation for exterior parts from a well-known North American electric vehicle company, with an expected total sales of 1.236 billion yuan [34] - Fulongma has pre-bid for five sanitation service projects in June, with a total contract amount of 181 million yuan [35] Group 9 - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange [36] - *ST Yuancheng is under investigation by the CSRC for suspected false financial disclosures [37] - Beilu Pharmaceutical's subsidiary has received approval for the listing of Iopamidol raw materials [38] Group 10 - Zhejiang Liming's shareholder plans to reduce their stake by up to 2.93% [39] - Zhejiang Liming's actual controller has committed not to reduce their holdings within a year [40] - SAIC Motor reported a total vehicle sales of 2.0526 million units in the first half of 2025, a year-on-year increase of 12.35% [41] Group 11 - Xinhongcheng expects a net profit increase of 50%-70% for the first half of 2025 [42] - Xianhe Co. plans to invest 11 billion yuan in a bamboo pulp paper integrated project [42] - Great Wall Motors reported a total vehicle sales of 569,800 units in the first half of 2025, a year-on-year increase of 1.81% [43] Group 12 - Dongfeng Co. received a government subsidy of 10 million yuan [44] - Zhongke Environmental Protection has acquired two water environmental companies in Guangxi for a total of 353 million yuan [45] - Anji Food's H-share public offering is priced at 60 Hong Kong dollars per share [46]